Status:
WITHDRAWN
"The Evaluation of Stimulant Withdrawal"
Lead Sponsor:
Aaron J. Janowsky
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Anxiety
Relapse
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetami...
Eligibility Criteria
Inclusion
- Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
- Must meet the clinical definition for methamphetamine dependence
- Self-reported methamphetamine use within 10 days of entering the study
- Must be able to understand and sign the consent form
Exclusion
- Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
- Pregnant or nursing mothers
- Psychosis
- Dementia
- Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
- History of withdrawal seizures or delirium tremors
- Use of MAO inhibitors within the last two weeks
- Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00442923
Start Date
July 1 2007
End Date
June 30 2011
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
US Veterans Hospital
Portland, Oregon, United States, 97239